E-ISSN: 1309-5749 | ISSN: 1018-8681 | Join E-mail List | Contact | Twitter
Review of the Diagnosis and Treatment of Pregnant Psychiatric Inpatients
1Recep Tayyip Erdogan University, Department of Psychiatry, Rize - Turkey
2Sisli Hamidiye Etfal Training and Research Hospital, Department of Psychiatry, Istanbul - Turkey
3Maltepe University, Department of Psychiatry, Istanbul - Turkey
4Sinop State Hospital, Sinop - Turkey
Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2016; 1(29): 96-98 DOI: 10.5350/DAJPN2016290112

Dear Editor,

Psychiatric disorder periods experienced during pregnancy are important because they affect both the pregnant woman and the fetus negatively (1,2). There is no standard treatment protocol specific for psychiatric patients during pregnancy. With the perspective to illuminate research into the diagnosis and prevention of potential risks, it is thought that a study evaluating data obtained from a review of patient files will be beneficial to avoid potential risks and to specify the treatment of psychiatric patients during pregnancy.

Data from 22 pregnant inpatients presenting to the psychiatry service of a Training and Research Hospital between August 2010 and August 2011 were evaluated retrospectively by reviewing the patient files. The most common psychiatric disorders experienced in the 1st and 2ndtrimesters were mood disorders. In the 3rd trimester, schizophrenia, major depressive disorder (MDD), and schizoaffective disorder (SAD) were seen equally. Psychiatric disorders found throughout pregnancy were schizophrenia (n=6; 27.5%), bipolar disorders (BD) manic attack (n=5; 23.0%), BD depressive attack (n=2; 9.0%), BD mixed attack (n=1; 4.5%), MDD (n=5; 22.5%), obsessive compulsive disorder (OCD) (n=1; 4.5%), and SAD (n=2; 9.0%). While psychotherapy was given to a patient in the form of cognitive behavioral therapy (CBT) in the 1sttrimester, electroconvulsive therapy (ECT) was used for the three patients with psychotic features and suicidal thoughts in the 2nd and 3rdtrimesters. A patient in her 7th gestational week with MDD who had taken venlafaxine before pregnancy and continued to do so when pregnant was found to have undergone spontaneous abortion. The OCD (schizo-obsessive) patient presenting in the 1st trimester was treated with ECT first; later, sertraline and CBT were added. In the 1st and 2nd trimesters, ECT and haloperidol were used in the patient with excited BD manic attack. In the patient suffering from BD mixed attack with suicidal thoughts in the 2nd trimester, after administering ECT, her pregnancy ended in an abortus. Two patients with BD depressive attack, self-medicating with lithium before presenting to the hospital were determined to be in the 2nd trimester. While one of the patients was taking lithium irregularly, the other one was using it regularly, having started a few months earlier. An advanced investigation was performed for these patients by gynecologists and specialist obstetricians. Due to major malformation detection, medical abortion was preformed in the patient who had used lithium irregularly before. In the other patient, no prominent malformation was found and lithium treatment was continued with the consultation by a gynecologist and obstetrician. In the 1st and 2ndtrimesters, schizophrenia patients with excitation and suicidal thoughts were treated by ECT, while only haloperidol was administered to those with neither of these symptoms. Olanzapine and quetiapine were given to the schizophrenia patients in the 3rd trimester, while ECT and haloperidol were applied to the patient in the 3rd trimester suffering from SAD. In another SAD patient, it was established that she had used clozapine and valproic acid before presenting to hospital in the 3rd trimester. No congenital defect was detected by the specialist gynecologist and obstetrician.

Selective serotonin reuptake inhibitors (SSRI) like sertraline and serotonin noradrenalin reuptake inhibitors (SNRI) like venlafaxine are used in MDD and OCD (2). Although there is no valid evidence for an increase of teratogenicity by using SSRI or SNRI, with the use of serotonergic antidepressants, like venlafaxine, adverse effects may be found (3). Our research is consistent with the literature. It is indicated that there are studies showing that CBT is as effective as medication in the treatment of mild-moderate MDD, but there is no published study on its effectiveness in the treatment of MDD during pregnancy yet (4,5).

In life-threatening cases, such as psychosis and suicidal thought, the importance of ECT becomes clear (6). In our research, clinicians took the patient’s treatment into consideration. Recent findings have shown that ECT is effective in perinatal mood disorders (7). ECT applied during pregnancy was examined retrospectively in the studies, and infant deaths were reported (8). We have found a similar result in our study. Unfortunately, no prospective, controlled studies inspecting ECT treatment in pregnancy have been carried out until now (7,8).

Clinicians prefer antipsychotic drugs to mood stabilizers as an alternative in the limited number of studies available (9-11). Though major malformations were detected after exposure to antipsychotic drugs such as haloperidol, olanzapine (10), quetiapine, and clozapine during pregnancy (9), it has been reported that no obvious malformations were seen in the case series and reports (11). Although lithium and valproic acid have a teratogenic effect, in some studies it was seen that these substances did not increase the incidence of major malformations. The negative information previously existing about these drugs was not confirmed by later research (12,13).

When these findings are taken into account, none of the psychotropic drugs required to be used during pregnancy is completely safe. It is very difficult to formulate a structured standardized treatment algorithm for pregnant psychiatric patients. Clinicians must select safe choices and should follow appropriate strategies in setting up personal treatment plans and in patient follow-up. In order to develop a treatment protocol, multicenter studies with more patients being analyzed both prospectively and retrospectively are necessary.


1.Cetin M. Psychotropic drug use in pregnancy: an update. Bulletin of Clinical Psychopharmacology 2011; 21:161-173. (Turkish) [CrossRef]

2.Koren G, Boucher N. Adverse effects in neonates exposed to SSRIs and SNRI in late gestation. Can J Clin Pharmacol 2009; 16:66-67.

3.Louik C, Lin AE, Werler MM, Hernanz Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356:2675-2683. [CrossRef]

4.Oguzhanoglu NK, Varma GS. The course of psychiatric disorders during pregnancy. Last Word in Psychiatry 2013; 3:276-287. (Turkish)

5.Hou Y, Hu P, Zhang Y, Lu Q, Wang D, Yin L, Chen Y, Zou X. Cognitive behavioral therapy in combination with systemic family therapy improves mild to moderate postpartum depression. Rev Bras Psiquiatr 2014; 36:47-52. [CrossRef]

6.Anderson EL, Reti IM. ECT in pregnancy: a review of the literature from 1941 to 2007. Psychosom Med 2009; 71:235-242. [CrossRef]

7.Yonkers KA, Vigod S, Ross LE. Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women. Obstet Gynecol 2011; 117:961-977. [CrossRef]

8.Alpay N, Karsidag C. Electroconvulsive therapy in pregnancy: a review. Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2006; 19:204-211. (Turkish)

9.Kohen D. Psychotropic medication in pregnancy. Adv Psychiatr Treat 2003; 10:59-66. [CrossRef]

10.Yeshayahu Y. The use of olanzapine in pregnancy and congenital cardiac and musculoskeletal abnormalities. Am J Psychiatry 2007; 164:1759-1760. [CrossRef]

11.Einarson A. Risks / safety of psychotropic medication use during pregnancy. Can J Clin Pharmacol 2009; 16:58-65.

12.Yacobi S, Ornoy A. Is lithium a real teratogen? What can we conclude from the prospective versus retrospective studies? A review. Isr J Psychiatry Relat Sci 2008; 45:95-106.

13.Alsdorf R, Wyszynski DF. Teratogenicity of sodium valproate. Expert Opin Drug Saf 2005; 4:345-53. [CrossRef]